Catalent (NYSE:CTLT) had its price objective raised by Robert W. Baird from $74.00 to $80.00 in a research report sent to investors on Friday, The Fly reports. They currently have an outperform rating on the stock.
CTLT has been the subject of several other reports. Royal Bank of Canada began coverage on shares of Catalent in a research report on Monday, April 20th. They issued an outperform rating and a $65.00 target price for the company. UBS Group boosted their target price on shares of Catalent from $70.00 to $77.00 and gave the company a buy rating in a research report on Wednesday, May 6th. Deutsche Bank boosted their target price on shares of Catalent from $59.00 to $62.00 and gave the company a hold rating in a research report on Wednesday, May 6th. Zacks Investment Research cut shares of Catalent from a buy rating to a hold rating in a research report on Friday, June 5th. Finally, Argus assumed coverage on shares of Catalent in a research report on Thursday, June 25th. They issued a buy rating for the company. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $74.71.
NYSE CTLT opened at $71.94 on Friday. The company has a quick ratio of 1.58, a current ratio of 1.90 and a debt-to-equity ratio of 1.34. The company has a market capitalization of $11.32 billion, a P/E ratio of 102.77, a P/E/G ratio of 4.35 and a beta of 1.65. Catalent has a 12-month low of $31.04 and a 12-month high of $80.52. The firm has a 50-day moving average price of $74.17 and a two-hundred day moving average price of $60.50.
Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.45 by $0.05. The firm had revenue of $760.60 million during the quarter, compared to the consensus estimate of $696.10 million. Catalent had a net margin of 4.79% and a return on equity of 14.58%. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.49 EPS. Equities analysts expect that Catalent will post 1.61 EPS for the current year.
In related news, insider Aristippos Gennadios sold 8,325 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $73.00, for a total transaction of $607,725.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.30% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Stephenson National Bank & Trust acquired a new position in Catalent in the 1st quarter valued at approximately $42,000. FDx Advisors Inc. boosted its stake in shares of Catalent by 390.1% in the 1st quarter. FDx Advisors Inc. now owns 35,318 shares of the company’s stock valued at $48,000 after purchasing an additional 28,112 shares during the last quarter. Shine Investment Advisory Services Inc. boosted its stake in shares of Catalent by 205.0% in the 1st quarter. Shine Investment Advisory Services Inc. now owns 2,019 shares of the company’s stock valued at $105,000 after purchasing an additional 1,357 shares during the last quarter. Pendal Group Ltd boosted its stake in shares of Catalent by 47.6% in the 1st quarter. Pendal Group Ltd now owns 2,421 shares of the company’s stock valued at $126,000 after purchasing an additional 781 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its stake in shares of Catalent by 79.7% in the 1st quarter. Exchange Traded Concepts LLC now owns 2,859 shares of the company’s stock valued at $149,000 after purchasing an additional 1,268 shares during the last quarter.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Article: Earnings Reports
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.